Atara Biotherapeutics (ATRA) Competitors

$9.34 -0.11 (-1.16%)

As of 04:00 PM Eastern

ATRA vs. ORIC, IVVD, NMRA, FENC, and CMPX

Should you buy Atara Biotherapeutics stock or one of its competitors? MarketBeat compares Atara Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Invivyd (IVVD), Neumora Therapeutics (NMRA), Adherex Technologies (FENC), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Oric Pharmaceuticals' return on equity of -35.33% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oric Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market.

In the previous week, Atara Biotherapeutics had 24 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 28 mentions for Atara Biotherapeutics and 4 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.24 beat Atara Biotherapeutics' score of 0.06 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals currently has a consensus price target of $19.36, suggesting a potential upside of 128.88%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential upside of 1.71%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Atara Biotherapeutics	$120.77M	0.70	$32.69M	-$0.67	N/A

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Invivyd?

Atara Biotherapeutics (NASDAQ:ATRA) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Atara Biotherapeutics has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

In the previous week, Atara Biotherapeutics had 10 more articles in the media than Invivyd. MarketBeat recorded 28 mentions for Atara Biotherapeutics and 18 mentions for Invivyd. Atara Biotherapeutics' average media sentiment score of 0.06 beat Invivyd's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Atara Biotherapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 1.71%. Invivyd has a consensus price target of $8.00, suggesting a potential upside of 620.72%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Atara Biotherapeutics has a net margin of -40.91% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Invivyd	-138.90%	-53.48%	-41.56%

Atara Biotherapeutics has higher revenue and earnings than Invivyd. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.70	$32.69M	-$0.67	N/A
Invivyd	$53.43M	6.12	-$52.49M	-$0.31	N/A

Summary

Atara Biotherapeutics and Invivyd tied by winning 8 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Atara Biotherapeutics had 27 more articles in the media than Neumora Therapeutics. MarketBeat recorded 28 mentions for Atara Biotherapeutics and 1 mentions for Neumora Therapeutics. Atara Biotherapeutics' average media sentiment score of 0.06 beat Neumora Therapeutics' score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neumora Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Neumora Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.33	N/A
Atara Biotherapeutics	$120.77M	0.70	$32.69M	-$0.67	N/A

47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neumora Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-181.70%	-119.15%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Neumora Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 314.41%. Atara Biotherapeutics has a consensus target price of $9.50, suggesting a potential upside of 1.71%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.56
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Atara Biotherapeutics beats Neumora Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Adherex Technologies?

Atara Biotherapeutics (NASDAQ:ATRA) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Atara Biotherapeutics has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.70	$32.69M	-$0.67	N/A
Adherex Technologies	$44.64M	7.71	-$9.74M	-$0.29	N/A

In the previous week, Atara Biotherapeutics had 23 more articles in the media than Adherex Technologies. MarketBeat recorded 28 mentions for Atara Biotherapeutics and 5 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.68 beat Atara Biotherapeutics' score of 0.06 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atara Biotherapeutics has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Atara Biotherapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 1.71%. Adherex Technologies has a consensus price target of $14.80, suggesting a potential upside of 48.45%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adherex Technologies	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adherex Technologies has a net margin of -17.12% compared to Atara Biotherapeutics' net margin of -40.91%. Adherex Technologies' return on equity of -43.87% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Summary

Adherex Technologies beats Atara Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Compass Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Atara Biotherapeutics has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Compass Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Compass Therapeutics' return on equity of -39.75% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Compass Therapeutics	N/A	-39.75%	-35.29%

Atara Biotherapeutics currently has a consensus target price of $9.50, suggesting a potential upside of 1.71%. Compass Therapeutics has a consensus target price of $13.60, suggesting a potential upside of 608.33%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Atara Biotherapeutics has higher revenue and earnings than Compass Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.70	$32.69M	-$0.67	N/A
Compass Therapeutics	$850K	406.79	-$66.49M	-$0.41	N/A

In the previous week, Atara Biotherapeutics had 20 more articles in the media than Compass Therapeutics. MarketBeat recorded 28 mentions for Atara Biotherapeutics and 8 mentions for Compass Therapeutics. Atara Biotherapeutics' average media sentiment score of 0.06 beat Compass Therapeutics' score of -0.17 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Therapeutics beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.15M	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-13.94	19.01	20.92	25.47
Price / Sales	0.70	278.84	521.15	73.36
Price / Cash	1.93	125.35	43.18	55.00
Price / Book	-2.26	6.90	9.98	7.00
Net Income	$32.69M	$24.23M	$3.55B	$335.16M
7 Day Performance	-2.61%	0.58%	0.40%	-0.29%
1 Month Performance	87.17%	-0.61%	-0.02%	1.18%
1 Year Performance	35.36%	63.26%	34.94%	34.78%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	1.187 of 5 stars	$9.34 -1.2%	$9.50 +1.7%	+35.0%	$84.15M	$120.77M	N/A	330	Trending News Analyst Upgrade Gap Down
ORIC Oric Pharmaceuticals	2.2294 of 5 stars	$7.93 -2.7%	$19.36 +144.2%	+48.3%	$843.67M	N/A	N/A	80
IVVD Invivyd	2.0896 of 5 stars	$1.13 -6.6%	$8.00 +608.0%	+34.7%	$342.19M	$55.87M	N/A	100	Earnings Report Analyst Forecast Analyst Revision
NMRA Neumora Therapeutics	2.5224 of 5 stars	$1.77 -3.8%	$7.67 +333.1%	+135.7%	$340.92M	N/A	N/A	108
FENC Adherex Technologies	4.0748 of 5 stars	$9.60 -1.5%	$14.80 +54.2%	+19.3%	$336.78M	$44.64M	N/A	10	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, IVVD, NMRA, FENC, and CMPX

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Invivyd?

Summary

How does Atara Biotherapeutics compare to Neumora Therapeutics?

Summary

How does Atara Biotherapeutics compare to Adherex Technologies?

Summary

How does Atara Biotherapeutics compare to Compass Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, IVVD, NMRA, FENC, and CMPX

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Is ORIC or ATRA more profitable?

Do institutionals and insiders hold more shares of ORIC or ATRA?

Which has more risk and volatility, ORIC or ATRA?

Does the media refer more to ORIC or ATRA?

Do analysts prefer ORIC or ATRA?

Which has higher valuation and earnings, ORIC or ATRA?

Summary

How does Atara Biotherapeutics compare to Invivyd?

Which has more volatility & risk, ATRA or IVVD?

Does the media prefer ATRA or IVVD?

Do analysts rate ATRA or IVVD?

Do institutionals & insiders believe in ATRA or IVVD?

Is ATRA or IVVD more profitable?

Which has stronger valuation and earnings, ATRA or IVVD?

Summary

How does Atara Biotherapeutics compare to Neumora Therapeutics?

Does the media refer more to NMRA or ATRA?

Which has more risk & volatility, NMRA or ATRA?

Which has better earnings & valuation, NMRA or ATRA?

Do insiders and institutionals hold more shares of NMRA or ATRA?

Is NMRA or ATRA more profitable?

Do analysts recommend NMRA or ATRA?

Summary

How does Atara Biotherapeutics compare to Adherex Technologies?

Which has higher valuation & earnings, ATRA or FENC?

Does the media refer more to ATRA or FENC?

Which has more volatility & risk, ATRA or FENC?

Do analysts recommend ATRA or FENC?

Do insiders & institutionals hold more shares of ATRA or FENC?

Is ATRA or FENC more profitable?

Summary

How does Atara Biotherapeutics compare to Compass Therapeutics?

Which has more risk & volatility, ATRA or CMPX?

Do institutionals and insiders believe in ATRA or CMPX?

Is ATRA or CMPX more profitable?

Do analysts rate ATRA or CMPX?

Which has stronger valuation & earnings, ATRA or CMPX?

Does the media prefer ATRA or CMPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools